| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sakai H et al. | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. | 2018 | Breast Cancer | pmid:29700710 |
| Higa GM | The microtubule as a breast cancer target. | 2011 | Breast Cancer | pmid:20862571 |
| Montemurro F | HER2 expression and efficacy of T-DM1. | 2014 | Breast Cancer Res. | pmid:25472666 |
| Perez EA et al. | Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. | 2014 | Breast Cancer Res. | pmid:24887458 |
| Barok M et al. | Trastuzumab emtansine: mechanisms of action and drug resistance. | 2014 | Breast Cancer Res. | pmid:24887180 |
| Barok M et al. | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. | 2011 | Breast Cancer Res. | pmid:21510863 |
| Baldassarre T et al. | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. | 2017 | Breast Cancer Res. | pmid:28974266 |
| Krop IE et al. | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. | 2016 | Breast Cancer Res. | pmid:26979312 |
| Diaby V et al. | Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. | 2017 | Breast Cancer Res. Treat. | pmid:28840424 |
| Le QA et al. | Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. | 2016 | Breast Cancer Res. Treat. | pmid:27572338 |
| Jacot W et al. | Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. | 2016 | Breast Cancer Res. Treat. | pmid:27167986 |
| Junttila TT et al. | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. | 2011 | Breast Cancer Res. Treat. | pmid:20730488 |
| Sibaud V et al. | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. | 2014 | Breast Cancer Res. Treat. | pmid:24929675 |
| Tanz R et al. | [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. | 2014 Jul-Aug | Bull Cancer | pmid:25091656 |
| Gonçalves A et al. | [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. | 2012 | Bull Cancer | pmid:23247898 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Monneret C and Florent JC | [Targeting of antitumor drugs with monoclonal antibodies]. | 2000 | Bull Cancer | pmid:11125291 |
| Guerin M et al. | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 | Bull Cancer | pmid:25790739 |
| Luduena RF et al. | N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041960 |
| Schibler MJ and Cabral FR | Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041962 |